Center-Authored Papers

Filters: Author is Forero, Andres  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP et al..  2013.  A Phase 1 Study Evaluating the Safety and Tolerability of Otlertuzumab (TRU-016), an Anti-CD37 Mono-specific ADAPTIRTM Therapeutic Protein in Chronic Lymphocytic Leukemia.. Blood. Abstract
N
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH et al..  2017.  NCCN Guidelines Insights: Breast Cancer, Version 1.2017.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(4):433-451. Abstract
Zelenetz AD, Abramson JS, Advani RH, Andreadis BC, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP et al..  2010.  NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.. Journal of the National Comprehensive Cancer Network : JNCCN. 8(3):288-334.
M
Carlson RW, Allred CD, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ et al..  2012.  Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(7):821-9. Abstract
I
Carlson RW, Allred CD, Anderson BO, Burstein HJ, Carter BW, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH et al..  2011.  Invasive breast cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(2):136-222.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH et al..  2016.  Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(3):324-54. Abstract
H
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A et al..  2011.  Hodgkin lymphoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(9):1020-58.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R et al..  2015.  Hodgkin lymphoma, version 2.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(5):554-86. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B et al..  2012.  Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(5):589-597. Abstract
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA et al..  2017.  Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(5):608-638. Abstract
B
Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ et al..  2013.  Breast cancer, version 3.2013: featured updates to the NCCN guidelines.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(7):753-60;quiz761. Abstract
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH et al..  2015.  Breast Cancer, Version 1.2016.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(12):1475-85. Abstract
Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ et al..  2014.  Breast cancer version 3.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(4):542-90. Abstract
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH et al..  2015.  Breast cancer version 2.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(4):448-75. Abstract
6
Yadav BS, Bansal A, Sharma SC, Javid SH, Anderson BO, Vaklavas C, Forero A, Ravi V, Patel S, Boudadi K et al..  2013.  A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer.. Seminars in oncology. 40(2):135-44.